Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Atrasentan
Therapeutic Area : Nephrology
Study Phase : Phase III
Sponsor : Novartis Pharmaceuticals Corporation
Deal Size : $3,500.0 million
Deal Type : Acquisition
Details : Through the acquisition, Novartis expands its portfolio with chinook's renal pipeline having 2 assets, CHK-01 (atrasentan hydrochloride), an oral endothelin A receptor antagonist and BION-1301 (zigakibart), an anti-APRIL monoclonal antibody, for Immunogl...
Product Name : CHK-01
Product Type : Other Small Molecule
Upfront Cash : $3,500.0 million
December 06, 2023
Lead Product(s) : Atrasentan
Therapeutic Area : Nephrology
Highest Development Status : Phase III
Sponsor : Novartis Pharmaceuticals Corporation
Deal Size : $3,500.0 million
Deal Type : Acquisition
Lead Product(s) : Atrasentan
Therapeutic Area : Nephrology
Study Phase : Phase III
Sponsor : Novartis Pharmaceuticals Corporation
Deal Size : $3,500.0 million
Deal Type : Acquisition
Novartis Completes Acquisition of Chinook Therapeutics
Details : Through the acquisition, Novartis expands its portfolio with chinook's renal pipeline having 2 assets, CHK-01 (atrasentan hydrochloride), an oral endothelin A receptor antagonist and BION-1301 (zigakibart), an anti-APRIL monoclonal antibody, for Immunogl...
Product Name : CHK-01
Product Type : Other Small Molecule
Upfront Cash : $3,500.0 million
November 08, 2023
Lead Product(s) : Atrasentan
Therapeutic Area : Nephrology
Highest Development Status : Phase III
Sponsor : Novartis Pharmaceuticals Corporation
Deal Size : $3,500.0 million
Deal Type : Acquisition
Lead Product(s) : CHK-336
Therapeutic Area : Rare Diseases and Disorders
Study Phase : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : CHK-336 is an oral small molecule LDHA inhibitor for the treatment of hyperoxalurias. It is being evaluated in a phase 1 clinical trial in healthy volunteers.
Product Name : CHK-336
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
November 04, 2023
Lead Product(s) : CHK-336
Therapeutic Area : Rare Diseases and Disorders
Highest Development Status : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Zigakibart
Therapeutic Area : Nephrology
Study Phase : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : BION-1301 (zigakibart) is a novel anti-APRIL monoclonal antibody with a potentially disease-modifying approach to treating IgA nephropathy by depleting Gd-IgA1, the pathogenic IgA variant, and reducing proteinuria.
Product Name : BION-1301
Product Type : Antibody
Upfront Cash : Inapplicable
July 28, 2023
Lead Product(s) : Zigakibart
Therapeutic Area : Nephrology
Highest Development Status : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : CHK-336
Therapeutic Area : Rare Diseases and Disorders
Study Phase : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Preclinically, CHK-336 potently inhibits LDHA, final enzymatic step in oxalate synthesis, exhibits a liver-targeted tissue distribution profile characterized by high concentrations in liver, key pharmacodynamic site of action to block oxalate production.
Product Name : CHK-336
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
December 04, 2022
Lead Product(s) : CHK-336
Therapeutic Area : Rare Diseases and Disorders
Highest Development Status : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Atrasentan
Therapeutic Area : Nephrology
Study Phase : Phase III
Sponsor : SVB Securities
Deal Size : $105.0 million
Deal Type : Public Offering
Chinook Therapeutics Announces Pricing of a $105 Million Public Offering
Details : Chinook intends to use the net proceeds from this offering to continue its phase 3 ALIGN and phase 2 AFFINITY trials of atrasentan, fund a phase 3 clinical trial of BION-1301, continue development of CHK-336 and prepare for the potential commercial launc...
Product Name : CHK-01
Product Type : Other Small Molecule
Upfront Cash : Undisclosed
May 25, 2022
Lead Product(s) : Atrasentan
Therapeutic Area : Nephrology
Highest Development Status : Phase III
Sponsor : SVB Securities
Deal Size : $105.0 million
Deal Type : Public Offering
Lead Product(s) : Atrasentan
Therapeutic Area : Nephrology
Study Phase : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : CHK-01 (atrasentan) is a potent and selective inhibitor of the endothelin A receptor that has potential to provide benefit in multiple chronic kidney diseases by reducing proteinuria and having direct anti-inflammatory and anti-fibrotic effects to preser...
Product Name : CHK-01
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
May 20, 2022
Lead Product(s) : Atrasentan
Therapeutic Area : Nephrology
Highest Development Status : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Zigakibart
Therapeutic Area : Nephrology
Study Phase : Phase I/ Phase II
Sponsor : Evotec
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : BION-1301 is a novel anti-APRIL monoclonal antibody currently in phase 1/2 clinical development for patients with IgAN. Blocking APRIL is a potentially disease-modifying approach to treating IgAN by reducing circulating levels of galactose-deficient IgA1...
Product Name : BION-1301
Product Type : Antibody
Upfront Cash : Inapplicable
May 19, 2022
Lead Product(s) : Zigakibart
Therapeutic Area : Nephrology
Highest Development Status : Phase I/ Phase II
Sponsor : Evotec
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Zigakibart
Therapeutic Area : Nephrology
Study Phase : Phase I/ Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : BION-1301 is a humanized IgG4 monoclonal antibody that blocks APRIL, a TNF-family cytokine believed to be implicated in IgAN and other indications, from binding to its receptors.
Product Name : BION-1301
Product Type : Antibody
Upfront Cash : Inapplicable
May 07, 2022
Lead Product(s) : Zigakibart
Therapeutic Area : Nephrology
Highest Development Status : Phase I/ Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Atrasentan
Therapeutic Area : Nephrology
Study Phase : Phase III
Sponsor : Komodo Health
Deal Size : Undisclosed
Deal Type : Collaboration
Details : Through this collaborative efforts with the IgA Nephropathy Foundation as well as the work at Chinook developing CHK-01 (atrasentan) and BION-1301 for IgA nephropathy, have learned that the patient journey can be daunting and isolating.
Product Name : CHK-01
Product Type : Other Small Molecule
Upfront Cash : Undisclosed
May 04, 2022
Lead Product(s) : Atrasentan
Therapeutic Area : Nephrology
Highest Development Status : Phase III
Sponsor : Komodo Health
Deal Size : Undisclosed
Deal Type : Collaboration